Maksim Labkouski
Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction. Acelyrin (NASDAQ:SLRN) shares traded ~4% higher in reaction.
Per the deal terms, Acelyrin (